US 2017/0320868 A1Published application

Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles

AssigneeCentrexion Therapeutics Corporation

InventorsDoris Riether, Florian Paul Christian Binder, Henri Doods, Stephan Georg Mueller, Janet Rachel Nicholson, Achim Sauer

Life of this patent

Estimating the term…

Abstract

This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.

Claims6

Dependent claims

A compound selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

Dependencies are inferred from the claim text.

Facts

Application: 15/491,035Filed 19 Apr 2017
Priority: EP 13168165.217 May 2013
Published: 9 Nov 2017
Term ends: Not estimatedThe source records don’t support an estimate.

Classification16 codes

C07D 417/12
Containing two hetero rings: linked by a chain containing hetero atoms as chain links
A61K 31/422
Oxazoles: not condensed and containing further heterocyclic rings
A61P 25/00
Drugs for disorders of the nervous system
A61P 25/02
Drugs for disorders of the nervous system: for peripheral neuropathies

Family

Application14/891,051Continuation · filed 13 Nov 2015
Application15/491,035Continuation
US 10,112,934 B2Related patent
US 2016/0102085 A1Published application
US 9,650,370 B2Related patent
US 2017/0320868 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results